| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 16.198 | 80.662 | 63.246 | 15.044 | 3.672 | 4.402 | 11.238 | 4.555 |
| Total Income - EUR | - | - | 16.198 | 80.662 | 63.804 | 15.837 | 4.198 | 4.872 | 11.493 | 4.555 |
| Total Expenses - EUR | - | - | 166 | 7.573 | 19.183 | 21.113 | 18.275 | 16.836 | 13.764 | 5.173 |
| Gross Profit/Loss - EUR | - | - | 16.032 | 73.089 | 44.621 | -5.276 | -14.077 | -11.964 | -2.271 | -618 |
| Net Profit/Loss - EUR | - | - | 15.546 | 70.669 | 43.015 | -5.627 | -14.188 | -12.096 | -2.271 | -618 |
| Employees | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Ilmans Research Medicine Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 5 | 3 | 34.134 | 23.299 | 12.971 | 3.718 | 0 | 673 |
| Current Assets | - | - | 16.233 | 82.496 | 46.340 | 32.191 | 27.266 | 17.454 | 8.949 | 2.696 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 0 | 5.752 | 3.456 | 527 | 371 | 373 | 1.228 | 884 |
| Cash | - | - | 16.233 | 76.744 | 42.884 | 31.664 | 26.895 | 17.081 | 7.722 | 1.812 |
| Shareholders Funds | - | - | 15.590 | 70.720 | 43.065 | -5.577 | -19.641 | -31.798 | -33.973 | -34.401 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 648 | 11.779 | 37.850 | 61.786 | 60.537 | 53.671 | 43.210 | 37.770 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Ilmans Research Medicine Srl